Printer Friendly

CNS, INC., ANNOUNCES FDA CLEARANCE TO MARKET

 CNS, INC., ANNOUNCES FDA CLEARANCE TO MARKET
 MINNEAPOLIS, Nov. 11 /PRNewswire/ -- CNS, Inc. (NASDAQ: CNXS),


announced that the FDA has recently given clearance under the 510(k) process to market two new products: the Respi-Pak(TM) and RT-Pak(TM). Fred Brooks, president of CNS, stated that both new products will enhance the sale of sophisticated CNS sleep laboratory diagnostic equipment by offering the sleep technologist the ability to very accurately record three to eight channels of crucial respiratory and auxiliary physiological data during a sleep study.
 Addition of these new physiological parameters, along with the currently recorded neurological, cardiac and other pulmonary parameters, will greatly enhance the diagnosis of sleep-associated problems such as excessive daytime sleepiness (EDS), inability to sleep (insomnia), chronic muscle and joint pain (fibromyalgia) and cessation of breathing (sleep apnea). CNS expects to begin shipments of the Respi-Pak and RT-Pak by December 1991.
 CNS, Inc., manufactures and markets on a global basis computer enhanced diagnostic equipment and consumable products for sleep disorder centers, operating rooms and home health care markets.
 -0- 11/11/91
 /CONTACT: Fred Brooks, president of CNS, 612-474-7600/
 (CNSX) CO: CNS, Inc. ST: Minnesota IN: MTC SU: PDT JS -- MN011 -- 2964 11/11/91 10:45 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 11, 1991
Words:203
Previous Article:CAMBRIDGE NEUROSCIENCE AWARDED ORPHAN DRUG STATUS FOR PRAMIRACETAM; PHASE III TRIALS TO BEGIN IN 1992
Next Article:COKE CONSOLIDATED SIGNS LETTER OF INTENT OT ACQUIRE OPERATIONAL CONTROL OF SUNBELT COCA-COLA; WOULD BE SECOND LARGEST COKE BOTTLER IN U.S.
Topics:


Related Articles
CNS ENTERS INTO A LICENSE AGREEMENT WITH CREATIVE INTEGRATION AND DESIGN; ANNOUNCES NEW PRESIDENT
ALCO INTERNATIONAL GROUP INC. RECEIVES FDA CLEARANCE
NABI SEEKS TO MARKET THIRD VIROCHEQC DIAGNOSTIC PRODUCT; VIROCHEQC I SERVES AS MULTI-CONSTITUENT CONTROL FOR HIV 1&2 AND HEPATITIS MARKERS
CNS, INC., REPORTS BREATHE RIGHT(TM)
CNS SETTLES LAWSUIT AGAINST BOLLINGER INDUSTRIES, INC.
CNS, INC., SAYS FDA HAS CLEARED BREATHE RIGHT NASAL STRIP FOR MARKETING AS SNORING REMEDY
CNS, INC., SAYS FDA HAS CLEARED BREATHE RIGHT NASAL STRIP FOR MARKETING AS SNORING REMEDY
CNS, INC., GETS FDA CLEARANCE TO MARKET BREATHE RIGHT STRIPS FOR TEMPORARY RELIEF OF NASAL CONGESTION AND STUFFY NOSE
CNS, INC., RECEIVES FDA CLEARANCE TO MARKET BREATHE RIGHT STRIPS FOR RELIEF OF BREATHING DIFFICULTIES CAUSED BY DEVIATED SEPTUM
Azur Pharma Announces the Licensing of Niravam, Parcopa, Kemstro and Fluxid From UCB.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters